

Date: 15 January 2020

Re: Freedom of Information Request
Ref: 359 - 2019

Thank you for your email dated the 13th December 2019, requesting information with regard to the treatment of Breast Cancer and Urothelial Cancer Patients.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer?

Abemaciclib + aromatase inhibitor* *aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole	Exempt under S.40
Abemaciclib + Fulvestrant	25
Alpelisib + Fulvestrant	0
Atezolizumab	Exempt under S.40
Bevacizumab	0
Eribulin	22

Everolimus + Exemestane	0
Fulvestrant as a single agent	0
Gemcitabine + paclitaxel	0
Lapatinib	Exempt under S.40
Neratinib	17
Olaparib	Exempt under S.40
Palbociclib + aromatase inhibitor* *aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole	191
Pertuzumab + trastuzumab + docetaxel	31
Ribociclib + aromatase inhibitor* *aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole	6
Ribociclib + Fulvestrant	6
Talazoparib	0
Herceptin SC	0
Herceptin IV	0
Transtuzumab biosimilar SC	9
Transtuzumab biosimilar IV	198
Trastuzumab emtansine	26
Other active systemic anti-cancer therapy **** (e.g. docetaxel, vinorelbine or capecitabine as a single agent)	31- Docetaxel as single agent 256 - Paclitaxel as single agent 54 - Capecitabine as single agent Other* 416 *Excludes Bisphosphonates and Denosumab/Faslodex)

2. How many patients are being treated for:

2a Neo-adjuvant breast cancer;	
Transtuzumab total SC	26
Transtuzumab total IV	Exempt under S.40

2b Adjuvant breast cancer;	
Transtuzumab total SC	114
Transtuzumab total IV	Exempt under S.40

3. In the past 3 months, how many Urothelial cancer patients were treated with;

Atezolizumab	11
Carboplatinum in combination with another agent	Exempt under S.40 - with Etoposide Exempt under S.40 - with Oxaliplatin 13 - with Gemcitabine
Carboplatinum single agent	0
Cisplatinum in combination with another agent	22 - with Gemcitabine
Cisplatinum single agent	0
Nivolumab	41
Pembrolizumab	14
Any other chemo regimen without cisplatinum or carboplatinum	Exempt under S.40 - Paclitaxel 8 - Fluorouracil + Mitomycin + RT Exempt under S.40 - Oxaliplatin + Modified de Gramont Exempt under S.40 - CAV Exempt under S.40 - Vinflunine Exempt under S.40 - Docetaxel Exempt under S.40 - Everolimus

Other active systemic anti-cancer therapy [please state]	7- Tivozanib Exempt under S.40 - Sunitinib Exempt under S.40 - Ramucirumab Exempt under S.40 - Rogaratinib 9 - Pazopanib 15 – Ipilimumab + Nivolumab 8 - Ipilimumab 35 - Cabozantinib 6 - Avelumab + axitinib Exempt under S.40 - Axitinib Exempt under S.40 - Enfortumab Vedotin Exempt under S.40 - Durvalumab + Tremelimumab Exempt under S.40 - Durvalumab
Palliative care only	Exempt under S.40* *Palliative care appointments during Oct-Dec 2019 whereby the patient was not on active treatment in the period.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>